$NRIX News

Morgan Stanley Maintains Overweight on Nurix Therapeutics, Raises Price Target to $38

UBS Maintains Buy on Nurix Therapeutics, Raises Price Target to $31

Nurix Therapeutics To Carry 40% Of Clinical Development Costs Of Bexobrutideg, Roche To Carry 60%

Nurix Therapeutics To Receive $700M In Funding As Part Of Collaboration Agreement With Roche, Up To $2.3B After Milestone Payments

Nurix Therapeutics Finalizes Collaboration Agreement With Roche Following Expiration Of Regulatory Waiting Period

Mizuho Maintains Outperform on Nurix Therapeutics, Raises Price Target to $34

Truist Securities Maintains Buy on Nurix Therapeutics, Raises Price Target to $34

RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $33

Stifel Maintains Buy on Nurix Therapeutics, Raises Price Target to $40

BTIG Reiterates Buy on Nurix Therapeutics, Maintains $32 Price Target

Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price Target

HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $34

Nurix Therapeutics Q2 EPS $(0.81) Misses $(0.74) Estimate, Sales $9.043M Miss $16.170M Estimate

Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $33

Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price Target

Nurix Therapeutics Deal With Roche Is Worth Betting On

Nurix to Present Updated CLL Drug Data at EHA 2026, Says Bexobrutideg Shows Durable Responses in CLL Trial

HC Wainwright & Co. Reiterates Buy on Nurix Therapeutics, Maintains $32 Price Target

Truist Securities Maintains Buy on Nurix Therapeutics, Raises Price Target to $32

BTIG Maintains Buy on Nurix Therapeutics, Raises Price Target to $32